This antibody-cytokine fusion protein was achieved by conjugating/fusing the Anti-CD20 IgG to RLI. It was expressed in CHO and purified with affinity chromatography. The immunocytokine retains the ability to bind the CD20 as well as the biological activity of RLI. Anti-CD20-RLI kept its binding capacity to CD20, CD16 and IL15 receptor and therefore fully retained both antibody effector functions (ADCC and CDC), and the cytokine potential of RLI. In a severe combined immunodeficiency (SCID) mouse model of disseminated residual lymphoma, anti-CD20-RLI was found to induce long-term survival of 90% of mice up to at least 120 days whereas RLI and RTX, alone or in combination, just delayed the disease onset. This immunocytokine was designed for treating leukemias, lymphomas, rheumatoid arthritis, and other autoimmune diseases.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.